Search CommunityWalk:


Cytomedix Inc

209 Perry Parkway
Suite 7
Gaithersburg, MD, USA

Category: Biomaterials & Tissue Regeneration

Used in the following map:

Maryland Biotech Industry Map

Cytomedix Inc is a biotechnology company that develops, sells and licenses biologically active regenerative therapies for wound care, angiogenesis, and inflammation. The company's primary focus is the utilization of platelets and platelet derivatives to manage wound healing. Its vision is to achieve a leadership position in the field of advanced tissue regeneration technologies.

Cytomedix's AutoloGel(TM) System is indicated for use in certain chronic wounds. The AutoloGel(TM) System utilizes a unique technology that enables rapid isolation and activation of platelet rich plasma (PRP) from a patient's own blood. The PRP is subsequently processed to produce a gel for application to the wound bed, re-establishing a balance needed for natural healing to occur. AutoloGel contains growth factors, cytokines and chemokines that are essential for exuding wounds, such as leg ulcers, pressure ulcers, and diabetic ulcers and for the management of mechanically or surgically-debrided wounds. Some of these cytokines and growth factors have been shown to mobilize white blood cells and stem cells, enhance cell proliferation, and/or reduce inflammation.

Cytomedix's product pipeline comprises of CT-112, an octapeptide sequence with demonstrated anti-inflammatory activity when administered either orally or parenterally. CT-112 may be particularly useful for therapeutic intervention into inflammatory mediated disease such as, but not limited to, autoimmune diseases, graft versus host disease, COPD, reperfusion injury and artherosclerosis.

Cytomedix has agreements with Sorin S.p.A., Millennia Holdings Inc, CellMedix Inc, National Wound Therapies, LLC, SafeBlood Technologies, Inc., Perfusion Partners and Associates, Inc., DePuy Spine, Inc. (Formerly DePuy AcroMed, Inc.), etc.